🤑 Diamond Card — De Favorites kaarten van Holland Casino

Bill Ackman, chief executive officer and portfolio manager of Pershing Square Capital Management, L. Meanwhile, Sachem Head, run by former Ackman protege Scott Ferguson, opened a new position in Salix, buying , shares. Adage Capital Management listed a new position of 50, shares, according to SEC documents. Editing by Andre Grenon.{/INSERTKEYS}{/PARAGRAPH} {PARAGRAPH}{INSERTKEYS}Svea Herbst-Bayliss 3 分で読む BOSTON Reuters - Wall Street's savviest investors are picking sides on Bill Ackman's new bet on Valeant Pharmaceuticals International Inc VRX. Viking Global Investors reduced its stake by more than half, to 4 million shares at the end of the quarter, while Jana Partners slashed its holdings 63 percent to 1. Valeant Chief Executive Officer Michael Pearson has engineered roughly deals, the most recent being earlier this year when the company outbid a rival to win Salix Pharmaceuticals. Rowe Price adding money, while Viking Global Investors and Jana Partners cut stakes. Reporting by Svea Herbst-Bayliss. Hound Partners increased its stake by 22 percent and reported holding 2. When the serial acquirer bought Salix Pharmaceuticals Ltd earlier this year, some investors were tempted to get in on the mergers and acquisitions boom now sweeping the drug industry. Brave Warrior trimmed its holding by 4 percent to 5. Ackman acknowledged, however, that Valeant is hard to value, and clearly some investors were worried enough to cut back. Speaking publicly about his bet for the first time earlier this month, Ackman called Valeant an early stage Berkshire Hathaway Inc BRKa. TO , with BlueMountain Capital and T. BlueMountain Capital Management raised its bet percent during the first quarter, buying , shares to boost its stake to , shares. Iridian Asset Management owned 3 million shares after cutting its holding by 22 percent. Rowe Price bought an additional 2.